• Brentuximab vedotin shows promise in high-risk pediatric Hodgkin lymphoma

    1 month ago - By Healio

    The replacement of vincristine with brentuximab vedotin in standard front-line treatment appeared safe and effective among children and adolescents with high-risk classical Hodgkin lymphoma, according to phase 2 study results.
    Results, published in Journal of Clinical Oncology, also showed the use of brentuximab vedotin enabled lower radiation exposure for this group.
    “When I started to look for ways to improve the outcome for our high-risk pediatric patients with Hodgkin lymphoma, brentuximab vedotin was soon to be approved for relapsed Hodgkin lymphoma in adults,”
    Read more ...